• News
  • Our Company
    • Our Story
    • Our Vision
    • CEO Statement
    • Board of Directors
    • Management
    • Advisers & Collaborators
  • Patients & Families
    • Alzheimer's Patients
    • Impact on Society
    • The Unmet Medical Need
  • R & D
    • Alzheimer's Disease
    • Our Programs
    • Specific Targeting of Toxic Aβ Oligomers
    • The AβCC Peptide™ Technology
  • Investors
    • Overview
    • Press Releases
      • English
      • Swedish
    • Presentations
    • The Share
      • Largest Shareholders
      • Rights Issue / Företrädesemission 2020
      • Previous Share Issuances
      • Analyst Coverage
    • Financial Reports
      • English
      • Swedish
    • Financial Calendar
    • Corporate governance
      • General Meetings
      • Auditor
      • Articles of Association
      • Board of Directors
      • Management
    • Certified Adviser
    • IR Contact
  • Contact
logo
  • News
  • Our Company
    • Our Story
    • Our Vision
    • CEO Statement
    • Board of Directors
    • Management
    • Advisers & Collaborators
  • Patients & Families
    • Alzheimer's Patients
    • Impact on Society
    • The Unmet Medical Need
  • R & D
    • Alzheimer's Disease
    • Our Programs
    • Specific Targeting of Toxic Aβ Oligomers
    • The AβCC Peptide™ Technology
  • Investors
    • Overview
    • Press Releases
      • English
      • Swedish
    • Presentations
    • The Share
      • Largest Shareholders
      • Rights Issue / Företrädesemission 2020
      • Previous Share Issuances
      • Analyst Coverage
    • Financial Reports
      • English
      • Swedish
    • Financial Calendar
    • Corporate governance
      • General Meetings
      • Auditor
      • Articles of Association
      • Board of Directors
      • Management
    • Certified Adviser
    • IR Contact
  • Contact
Home / News

News

2021-03-03

Alzinova collaborates with Captario to optimize clinical development

Alzinova has recently initiated a collaboration with Captario to further optimize the company's development strategies. Read more

2021-03-01

Redeye interview with CEO Kristina Torfgård – webcast (in Swedish)

Alzinova's CEO Kristina Torfgård was interviewed on February 26, 2021 by Redeye’s Life Science analyst Anders Hedlund. Read more

2021-02-25

Alzinova Year End Report

"2020 was an important year and, our goal-oriented work has ensured that we are well prepared for the start… Read more

Image for Biomarker collaboration with Sahlgrenska University Hospital

2021-02-10

Biomarker collaboration with Sahlgrenska University Hospital

Alzinova is collaborating with prominent researchers at Sahlgrenska University Hospital in Gothenburg, Sweden, to track markers of neurodegenerative change… Read more

Image for “Alzinova: Another external validation”

2021-01-18

“Alzinova: Another external validation”

In a Research Note posted last week, equity research and investment banking company, Redeye, commented on “another external validation”… Read more

Image for 21 September – World Alzheimer’s Day

2020-09-14

21 September – World Alzheimer’s Day

World Alzheimer's Day takes place on 21 September and is part of World Alzheimer's Month, raising awareness for this disease… Read more

Image for Alzinova moves into the BioVentureHub

2020-06-16

Alzinova moves into the BioVentureHub

Alzinova, a Swedish biopharmaceutical company developing disease-modifying treatments against Alzheimer’s Disease, has moved into AstraZeneca’s BioVentureHub in Gothenburg. Read more

  • News
  • Our Company
  • Patients & Families
  • R & D
  • Investors
  • Contact

Alzinova AB. Pepparedsleden 1, SE-431 83, Mölndal, Sweden
+46 (0) 708 467 975   info@alzinova.com

Follow us on

follow us on linkedin